A New Revolution in Pain Measurement and Management with AI
Pain affects up to 1.9 Billion people globally, with a massive associated healthcare costs. Measuring pain has always been a challenge in the healthcare industry as each individual has different pain tolerance level and medical practitioners are always left to work on an assumption. Many tests are too one-dimensional and only measure pain at one point of time, mostly determined by the physician.
What if physicians are able to objectively assign a value to pain and potentially transform how clinicians assess and manage their patients to result in a more optimal care pathway?
That is the vision of Mundipharma as they announced the development of painfocusTM, a revolutionary new end-to-end pain management solution that significantly increases the objectivity of pain measurement, something that has been historically difficult. This has the potential to completely transform how caregivers and doctors manage their patients’ pain.
Leveraging on Biofourmis’ biovitalsTManalytics engine, painfocusTMuses advanced machine learning that combines multiple physiology biomarkers captured using wearable devices to calculate the presence and severity of pain.
The app can capture, monitor and analyse data generated by patients in an inpatient or outpatient setting, and share with caregivers an accurate picture of health including level of pain, quality of life and general physiology in real-time via a web-based dashboard.
This remarkable device also enables digital patient-caregiver communication, which is particularly significant for patients who don’t have the ability to verbally explain how they’re suffering.
painfocusTMhas been tested in an early feasibility study conducted in multiple hospitals in South Africa from January to May 2018 that continuously monitored the physiology of knee arthroplasty patients using Everion® physiology monitor. The study found significant correlations between patient-reported pain scores and the results calculated by painfocusTMin an ambulatory, real-world setting.
Mundipharma’s latest digital healthcare solution was developed and tested in partnership with leading digital health technology company Biofourmis, which specializes in augmenting personalized care with digital therapeutics.
painfocusTMwill further be evaluated in an investigator-initiated study in multiple public hospitals in Singapore, on how this solution can augment clinical care for patients in treatment. The study is being funded by Mundipharma.
